Epoch Investment Partners Inc. Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Epoch Investment Partners Inc. grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 57.7% during the second quarter, HoldingsChannel reports. The firm owned 163,296 shares of the biopharmaceutical company’s stock after purchasing an additional 59,745 shares during the quarter. Epoch Investment Partners Inc.’s holdings in Regeneron Pharmaceuticals were worth $171,629,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in REGN. West Paces Advisors Inc. boosted its stake in Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 23 shares during the last quarter. Stephens Consulting LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $26,000. Sachetta LLC lifted its stake in shares of Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares in the last quarter. Crewe Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $28,000. Finally, Lynx Investment Advisory acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $33,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Activity

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Bonnie L. Bassler sold 756 shares of the firm’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total value of $802,872.00. Following the completion of the sale, the director now owns 1,382 shares in the company, valued at $1,467,684. The disclosure for this sale can be found here. In the last three months, insiders sold 10,026 shares of company stock valued at $11,498,705. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.4 %

NASDAQ:REGN opened at $1,145.03 on Friday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $769.19 and a 52 week high of $1,211.20. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. The company has a market cap of $126.17 billion, a PE ratio of 33.83, a P/E/G ratio of 3.93 and a beta of 0.12. The business’s 50 day moving average is $1,131.75 and its two-hundred day moving average is $1,032.21.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. During the same period last year, the business posted $8.79 earnings per share. The firm’s revenue for the quarter was up 12.3% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on REGN shares. JPMorgan Chase & Co. lifted their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, September 16th. TD Cowen increased their target price on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Barclays boosted their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Finally, Piper Sandler increased their price objective on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a research report on Friday, August 23rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $1,111.30.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.